Fundraising FoxJohnson & Johnson Innovation – JJDC — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.
BiotechHealthtechLongevity
Co-investorsAtlas VentureDroia VenturesEcoR1 CapitalGV (Google Ventures)The Column GroupAbbVie+3 more
Alessa develops SaaS compliance software that combines KYC, KYB, AML, and fraud prevention tools for financial institutions and corporates globally.
CybersecurityEnterprise SoftwareFintechSaaSJamaica, JM
Holly Sais Phillippi(Chief Executive Officer)in
Co-investorsMassMutual VenturesMission BiocapitalSalesforce VenturesWavecrest Growth Partners
Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.
AI & Machine LearningBiotechSouth San Francisco, US
Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)
Co-investorsBerkeley CatalystDCVC (Data Collective)Droia VenturesFelicis VenturesMPM BioImpactRA Capital+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.